HRQOL improvements in anemic CKD patients treated with darbepoetin alfa (Aranesp™)

被引：0
|
作者：
Ruhman, SN
Heifner, KJ
Fadem, SZ
Melvor, ME
Brenner, RM
Powers, KM
Ford, JM
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] St Petersburg Heart Ctr, St Petersburg, FL USA
[3] Huston Kidney Ctr, Houston, TX USA
[4] Renal Associates, Little Rock, AR USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2002年 / 39卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
66
引用
收藏
页码：A27 / A27
页数：1
相关论文
共 50 条
  • [41] Dose response of darbepoetin alfa is similar in anemic patients with solid tumors or lymphoproliferative malignancies.
    Hedenus, M
    Glaspy, J
    Dewey, C
    O'Byrne, J
    Colowick, A
    BLOOD, 2001, 98 (11) : 297A - 298A
  • [42] Aranesp® (Darbepoetin alfa) administered once monthly maintains hemoglobin levels in patients with chronic kidney disease.
    Walczyk, M
    Agarwal, A
    Ling, B
    Carroll, W
    Liu, W
    Brenner, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 770A - 770A
  • [43] Mortality Risk of Darbepoetin Alfa Versus Epoetin Alfa in Patients With CKD: Systematic Review and Meta-analysis
    Wilhelm-Leen, Emilee R.
    Winkelmayer, Wolfgang C.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 66 (01) : 69 - 74
  • [44] FACTORS INFLUENCING THE FIRST DARBEPOETIN ALFA DOSING FREQUENCY CHANGE IN CKD PATIENTS NOT ON DIALYSIS
    Galle, Jan
    Claes, Kathleen
    Di Giulio, Salvatore
    Guerin, Alain
    Herlitz, Hans
    Kiss, Istvan
    Wirnsberger, Gerhard
    Manamley, Nick
    Addison, Janet
    Fouqueray, Bruno
    Froissart, Marc
    Winearls, Christopher
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 362 - 363
  • [45] Long-term followup of patients with anemia of CKD treated with once monthly (QM) de novo darbepoetin alfa (DA).
    Chalhoub, Elias
    Ismail, Khaled
    Faber, Mark D.
    Fayad, Rami
    Frinak, Stanley
    Yee, Jerry
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (04) : A33 - A33
  • [46] COST EFECTIVNESS OF DARBEPOETIN ALFA VERSUS EPOETIN ALFA IN THE MANAGEMENT OF ANEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE:HEALTH INSURANCE PERSPECTIVE
    Fouad, S.
    VALUE IN HEALTH, 2016, 19 (07) : A589 - A589
  • [47] Treatment of anemia with Aranesp® (darbepoetin-alfa) given once every two weeks in HIV seropositive patients.
    Tulpule, A
    Dharmapala, D
    Burian, P
    Espina, BM
    Jayne, G
    George, S
    Levine, AM
    BLOOD, 2004, 104 (11) : 849A - 849A
  • [48] Feasibility to increase the dosing interval of darbepoetin alfa (Aranesp®) to once monthly (QM) in patients with chronic renal insufficiency (CRI)
    van Manen, JG
    Bakker-de Bruin, Y
    Boeschoten, EW
    van Buren, M
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V258 - V258
  • [49] Exposure-Response Modeling of Darbepoetin Alfa in Anemic Patients With Chronic Kidney Disease Not Receiving Dialysis
    Doshi, Sameer
    Chow, Andrew
    Perez Ruixo, Juan Jose
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 75S - 90S
  • [50] Effects of Aerobic Exercise Training in Anemic Cancer Patients Receiving Darbepoetin Alfa: A Randomized Controlled Trial
    Courneya, Kerry S.
    Jones, Lee W.
    Peddle, Carolyn J.
    Sellar, Christopher M.
    Reiman, Tony
    Joy, Anil A.
    Chua, Neil
    Tkachuk, Linda
    Mackey, John R.
    ONCOLOGIST, 2008, 13 (09): : 1012 - 1020
12345